The Biggest Biotech News of 2017: What Happened This Year?
Still catching up on news? We've picked out the most exciting things that happened besides…
Still catching up on news? We've picked out the most exciting things that happened besides…
Data presented at ASH 2017 shows that Servier and Pfizer's UCART19, an allogeneic CAR-T therapy…
Turkey, roast potatoes, gravy, pigs in blankets... For me, food is an essential part of…
European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’…
Update (28/06/2017): Cellectis has announced the first administration of UCART123 in its Phase I trial…
In the US, the first CRISPR-edited crops were able to bypass GMO regulations, but Europe's…
Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around…
Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances…
David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and…
Before the “who to recruit” phase, an important question is “where?” We ran through the…
While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for…
The world's biggest biotech investor conference, hosted by JP Morgan, is now underway in San…